


# PRODUCT INFORMATION



## MHY908

Item No. 18293

**CAS Registry No.:** 1393371-39-5  
**Formal Name:** 2-[4-(5-chloro-2-benzothiazolyl)phenoxy]-2-methyl-propanoic acid  
**MF:** C<sub>17</sub>H<sub>14</sub>ClNO<sub>3</sub>S  
**FW:** 347.8  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 217, 310, 324 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

MHY908 is supplied as a crystalline solid. A stock solution may be made by dissolving the MHY908 in the solvent of choice, which should be purged with an inert gas. MHY908 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of MHY908 in these solvents is approximately 1, 10, and 25 mg/ml, respectively.

MHY908 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, MHY908 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. MHY908 has a solubility of approximately 0.1 mg/ml in a 1:8 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

MHY908 is a dual agonist of peroxisome proliferator-activated receptor α (PPARα) and PPARγ that increases transcriptional activity of PPARα and PPARγ in a luciferase reporter assay in AC2F rat liver cells when used at a concentration of 5 μM.<sup>1</sup> *In vivo*, MHY908 (3 mg/kg per day) reduces serum glucose, triglyceride, and insulin levels and improves hepatic steatosis by reducing hepatic triglyceride levels and lipid droplet accumulation in *db/db* mice and 20-month-old rats.<sup>1,2</sup> It reduces peroxynitrite and COX-2 levels, reactive oxygen species (ROS) production, and Akt phosphorylation in isolated kidney from 20-month-old rats when administered at a dose of 3 mg/kg.<sup>2</sup> MHY908 inhibits mushroom tyrosinase (IC<sub>50</sub> = 8.19 μM).<sup>3</sup> It also inhibits increases in melanin content in α-melanocyte stimulating hormone-induced B16/F10 murine melanoma cells when used at a concentration of 10 μM.

### References

1. Park, M.H., Park, J.Y., Lee, H.J., *et al.* Potent anti-diabetic effects of MHY908, a newly synthesized PPARα/γ dual agonist in *db/db* mice. *PLoS One* **8**(11), e78815 (2013).
2. Park, M.H., Kim, D.H., Kim, M.J., *et al.* Effects of MHY908, a new synthetic PPARα/γ dual agonist, on inflammatory responses and insulin resistance in aged rats. *J. Gerontol. A Biol. Sci. Med. Sci.* **71**(3), 300-309 (2016).
3. Park, M.H., Kim, S.J., Jeong, H.O., *et al.* Inhibition of melanogenesis by 2-[4-(5-chlorobenzo[d]thiazol-2-yl)phenoxy]-2-methylpropanoic acid (MHY908). *Arch. Pharm. Res.* **38**(4), 505-511 (2015).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/10/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM